Latest news with #AmericanUrologicalAssociationAnnualMeeting
Business Insider
29-04-2025
- Business
- Business Insider
CG Oncology Stock (CGON) Surges 25% As Cancer Drug Shows Remarkable Results
CG Oncology (CGON) shares rocketed 25% higher on Monday, with trading volume exploding as investors responded enthusiastically to newly released clinical trial data. The biotech company, focused on developing innovative bladder cancer treatments, has now enjoyed four consecutive days of gains, climbing over 34% over the past week. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. The dramatic price surge follows the company's presentation of highly promising clinical trial results at the American Urological Association Annual Meeting this past weekend. Breakthrough Results in Bladder Cancer Treatment The excitement centers around CG Oncology's lead drug candidate, cretostimogene grenadenorepvec, which demonstrated exceptional effectiveness in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The Phase 3 BOND-003 trial revealed a 42.3% complete response rate at the 24-month mark, significantly higher than previous treatment options for this difficult-to-treat condition. Perhaps most impressive, 97.3% of patients receiving the treatment remained free from progression to muscle-invasive bladder cancer after two years. The drug also maintained a strong safety profile, with researchers reporting no serious treatment-related adverse events among trial participants. 'These results represent best-in-disease durability data,' noted clinical investigators at the conference, highlighting the potential transformative impact for patients who currently have limited treatment options and often face the prospect of complete bladder removal. Market Implications and Analyst Response With Monday's close, CGON stock has nearly doubled from its January IPO price, signaling strong investor confidence in its innovative approach to bladder cancer treatment. Wall Street has also responded favorably to the news, with analysts maintaining a consensus 'Strong Buy' rating on CG Oncology's shares. The average price target for CGON stock is $61.00, representing a potential upside of 118.09% from current levels. The strong clinical data suggests a reduced regulatory risk and increased likelihood of eventual FDA approval, a critical milestone for any biotech company. Institutional interest has grown alongside the positive clinical results, with 90 institutions recently adding to their CGON positions, though some insider selling has occurred over the past six months. Looking Ahead The market reaction reflects growing confidence that cretostimogene could become a preferred treatment option in a substantial and growing market. With bladder cancer ranking as one of the most expensive cancers to treat, a breakthrough therapy could generate significant revenue. Nevertheless, the impressive durability and efficacy data position CG Oncology favorably against competitors in the space. If regulatory progress continues smoothly, analysts expect further upward revisions to revenue projections and potentially additional price appreciation for this emerging player in the oncology treatment landscape.
Yahoo
27-04-2025
- Business
- Yahoo
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
Data Presented at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada PRINCETON, N.J., April 27, 2025--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights a duration of response of nearly four years from a long-term follow-up study with JELMYTO® (mitomycin) for pyelocalyceal solution, which is FDA-approved for the treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients. Among patients from the OLYMPUS trial who achieved a complete response after primary chemoablation with JELMYTO (n=41), the median duration of response was 47.8 months, irrespective of whether their cancer was new-onset or recurrent (median follow-up 28.1 months [95% CI 13.1, 57.5]). Of these patients, 21 had new-onset UTUC, and 20 had recurrent UTUC at baseline; there were no significant differences in durability between groups, with 8 patients in each group experiencing recurrence or death not due to treatment. Twenty patients entered long-term follow-up with a median follow-up of 53.3 months (95% CI 27.9, 65.3); median duration of response was not estimable (95% CI 43.5, not estimable) due to the low event rate. "This sub-analysis highlights new evidence for the impressive long-term benefits of JELMYTO, in both new-onset and recurrent low-grade upper tract urothelial cancer patients," said Brian Hu, MD, Associate Professor of Urology at Loma Linda University Health, CA. "These findings further establish JELMYTO as an effective treatment, providing patients with durable responses and a significant reduction in recurrence rates." LG-UTUC is a challenging disease often managed through endoscopically guided ablation, but recurrence is common, and patients face a lifetime of surveillance and potential complications. The OLYMPUS Phase 3 trial evaluated JELMYTO, a reverse thermal gel containing mitomycin (4 mg/mL), as a primary treatment for adults with LG-UTUC. While the overall trial demonstrated the potential of JELMYTO to significantly eradicate disease, this sub-analysis focuses specifically on patients with new-onset and recurrent LG-UTUC who achieved a complete response, providing new insights into the durability and long-term effectiveness of the treatment. Limitations of this study include the post-hoc nature of the analysis and potential selection bias regarding entry of patients into long-term follow-up. "We are encouraged by the long-term outcomes evidence observed in both new-onset and recurrent LG-UTUC patients," said Mark Schoenberg, MD, Chief Medical Officer, UroGen. "The sub-analysis provides further compelling evidence that JELMYTO offers durable disease control and clinically meaningful responses, which could significantly reduce the need for repeated interventions. We look forward to expanding our understanding of JELMYTO through the ongoing uTRACT Registry and further evaluating its potential in real-world settings." To further explore the potential of JELMYTO in treating patients with LG-UTUC, investigators are currently enrolling participants in the JELMYTO uTRACT Registry (NCT05874921) to gather longitudinal real-world usage data. As of April 2025, 22 sites have been activated with 251 patients enrolled. About JELMYTO JELMYTO® (mitomycin) for pyelocalyceal solution is a mitomycin-containing reverse thermal gel containing 4 mg mitomycin per mL gel approved for the treatment of adult patients with LG-UTUC. JELMYTO is a viscous liquid when cooled and becomes a semi-solid gel at body temperature. The drug slowly dissolves over four to six hours after instillation and is removed from the urinary tract by normal urine flow and voiding. It is approved for administration in a retrograde manner via ureteral catheter or antegrade through a nephrostomy tube. The delivery system allows the initial liquid to coat and conform to the upper urinary tract anatomy. The eventual semisolid gel allows for chemoablative therapy to remain in the collecting system for four to six hours without immediately being diluted or washed away by urine flow. About Upper Tract Urothelial Cancer Urothelial cancer is the ninth most common cancer globally and the eighth most lethal neoplasm in men in the U.S. Between five percent and ten percent of primary urothelial cancers originate in the ureter or renal pelvis and are collectively referred to as UTUC. In the U.S., there are approximately 6,000 - 7,000 new or recurrent LG-UTUC patients annually. Most cases are diagnosed in patients over 70 years old, and these older patients often have multiple comorbidities. There are limited treatment options for UTUC, with the most common being endoscopic surgery or nephroureterectomy (removal of the entire kidney and ureter). Treatment with endoscopic surgery can be associated with a high rate of recurrence and relapse. About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit to learn more or follow us on X (Twitter), @UroGenPharma. APPROVED USE FOR JELMYTO JELMYTO® is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC). IMPORTANT SAFETY INFORMATION You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract. Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you: are pregnant or plan to become pregnant. JELMYTO can harm your unborn baby. You should not become pregnant during treatment with JELMYTO. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO and for 6 months after the last dose. Males being treated with JELMYTO: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if JELMYTO passes into your breast milk. Do not breastfeed during treatment with JELMYTO and for 1 week after the last dose. Tell your healthcare provider if you take water pills (diuretic). How will I receive JELMYTO? Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO treatment. You will receive your JELMYTO dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses. JELMYTO is given to your kidney through a tube called a catheter. During treatment with JELMYTO, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving JELMYTO: JELMYTO may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. JELMYTO may cause serious side effects, including: Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO. Bone marrow problems. JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. Your healthcare provider may need to temporarily or permanently stop JELMYTO if you develop bone marrow problems during treatment with JELMYTO. The most common side effects of JELMYTO include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1800FDA1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please see JELMYTO Full Prescribing Information, including the Patient Information, for additional information. Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: future results or outcomes implied from the long-term follow up study data; the estimated patient population and demographics for UTUC; the potential of UroGen's proprietary RTGel technology to improve therapeutic profiles of existing drugs; and UroGen's sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as "could," "encourage," "potential" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: prior results may not be indicative of results that may be observed in the future; potential safety and other complications from JELMYTO use in diverse UTUC patient types; the timing and success of clinical trials and potential safety and other complications thereof; unforeseen delays that may impact the timing of progressing clinical trials and reporting data; the ability to obtain regulatory approval within the timeframe expected, or at all; the ability to obtain and maintain adequate intellectual property rights and adequately protect and enforce such rights; complications associated with commercialization activities; the labeling for any approved product; competition in UroGen's industry; the scope, progress and expansion of developing and commercializing UroGen's product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; UroGen's ability to attract or retain key management, members of the board of directors and other personnel; RTGel technology may not perform as expected; and UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 10, 2025, The events and circumstances discussed in such forward-looking statements may not occur, and UroGen's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release. View source version on Contacts INVESTOR CONTACT: Vincent PerroneSenior Director, Investor 609-460-3588 ext. 1093 MEDIA CONTACT:Cindy RomanoDirector, Corporate 609-460-3583 ext. 1083 Sign in to access your portfolio
Yahoo
24-04-2025
- Health
- Yahoo
Teleflex Announces Clinical and Real-World Evidence Studies and Physician Educational Opportunities to Be Highlighted at the 2025 American Urological Association (AUA) Annual Meeting
Experienced Urologists to Present Latest Findings and Host Multiple Educational Sessions WAYNE, Pa., April 24, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the presentation of several clinical studies at the 2025 American Urological Association Annual Meeting, which is being held in Las Vegas from April 26 - 29, 2025. These studies contribute to the expanding body of clinical and real-world evidence supporting innovations in benign prostatic hyperplasia (BPH) treatment and rectal spacing to protect tissue during radiation treatment for prostate cancer. 'Understanding how leading treatment options perform—both in rigorous clinical trials and in everyday practice—is essential to empowering the future of healthcare for patients,' said Travis Gay, president and general manager of Teleflex Interventional Urology. 'At Teleflex, we are deeply committed to advancing evidence-based innovation. Through ongoing real-world clinical trial research, we continue to support the safe and effective use of the UroLift™ System and Barrigel™ rectal spacer, helping physicians enhance outcomes and quality of life for patients.'Clinical Study Presentations: Results from the CLEAR Randomized Controlled Trial (RCT) Suggest Factors Corresponding to Early Patient Satisfaction Are Better Following UroLift PUL Versus Rezum WVTT†Moderated Poster Presentation; Saturday, April 26, 3:30–5:30 pm in Casanova, Room 505The CLEAR randomized controlled trial compares patient outcomes between UroLift™ PUL and Rezum WVTT.1 The presentation is being moderated by Dr. Bilal Chughtai*, urologist, Northwell Health, Garden City, N.Y. Patients Dissatisfied with BPH Medication in the IMPACT RCT Demonstrate Worse Patient Experience and Sleep Quality Before Crossing Over to UroLift PUL.† – Podium Presentation; Saturday April 26, 1:00–3:00 pm in Galileo, Room 901The IMPACT randomized controlled trial evaluates safety, efficacy, and patient experience in BPH patients treated with UroLift™ PUL versus medication (tamsulosin).2 The presentation is presented by Dr. Dean Elterman*, associate professor of urology, the University of Toronto. Using the American Urological Association Quality Registry (AQUA) BPH Dataset to Assess Early Symptom Improvement after Treatment. Moderated Poster Presentation; Saturday, April 26, 3:30–5:30 Casanova 505. An analysis utilizing the AQUA database moderated by Dr. Claus Roehrborn*, Professor and Chairman, Department of Urology, University of Texas Southwestern Medical Center, Dallas, Tex.3 Safety of Stabilized Hyaluronic Acid (sHA) as a Rectal Spacer: Low Risk of Rectal Wall Infiltration (RWI) and Reversibility – Poster Session; Tuesday, April 29, 9:30 – 11:30 am in Marco Polo 703 A research team in Australia, led by Professor Dr. Michael Chao*, a radiation oncologist at the Olivia Newton John Cancer Wellness & Research Centre in Victoria, Australia, conducted a study on the safety of sHA rectal spacers in cases of RWI.4 Teleflex and AUA are also hosting multiple educational events: 'Semi-Live Barrigel Case Review and Discussion' on Saturday, April 26, 2:35 – 3:05 pm in the Venetian Ballroom. In this AUA event, Dr. Varun Sundaram*, a urologist with Urology Austin, in Tex., will present insights from a recent Barrigel™ rectal spacer case, offering commentary and technical guidance on spacing procedures. This is an AUA event for which Teleflex provided funding. The second annual advanced practice provider (APP) educational breakfast, 'Engaging the APP in an Efficient Urology Practice' on Sunday, April 27, 6:45 – 8:00 am in Palazzo Ballroom B. Dr. Gregg Eure* with University of Virginia Health, Culpeper, Va.; Janelle Bunce*, PA-C with Advanced Urology Institute in Naples, Fla.; and Jamie Giovanelli*, PA-C with Urology of Virginia in Suffolk, Va. will discuss how to empower APPs to support the patient care pathway for patients with BPH and lower urinary tract symptoms. The discussion will center on the role of the APP in minimally invasive surgical therapies, including ultrasound gland sizing, if within scope of practice; in-office post procedure observations; and return post-op visits. Prostate Health Symposium, 'Transforming Quality of Life Through Personalized Prostate Care' on Sunday, April 27, 5:15 – 8:00 pm at Allegiant Stadium. In this first-ever combined UroLift™ System and Barrigel™ rectal spacer forum, a panel of experienced physicians—Dr. Zachary Klaassen*, urologic oncologist with Augusta University Medical Center/Georgia Cancer Center; Dr. Olubayo Tojuola*, urologist with Memorial Hermann Hospital at Houston, Tex.; and Dr. Ned Ruhotina*, a urologist with Associated Medical Professionals in Syracuse, N.Y.—will share real-world techniques for optimizing prostate radiation therapy with Barrigel™ rectal spacer and enhancing BPH outcomes with the UroLift™ System. In addition to these events, presentations will take place daily at Teleflex booth 1401 as follows: Presentations focused on Barrigel™ rectal spacer: Zachary Klaassen, MD, MSC* – Getting Started with Barrigel Rectal SpacerSaturday, April 26, 3:00 pm Anne Hong, MD* – RWIs & ReversibilitySunday, April 27, 11:00 am Presentations focused on UroLift™ System: David Sussman, DO, FACOS* – The Importance of Implant Density & Updates Regarding Recent PublicationsSaturday, April 26, 1:30 pm Silvia Secco, MD* – UroLift System: Surgical Experience & Competitive AdvantagesSunday, April 27, 1:30 pm For more information about the UroLift System, visit and for more information about Barrigel Rectal Spacer, visit About the UroLift™ SystemThe UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift™ System permanent implants, which can be delivered during an outpatient procedure,5 relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.6 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.**7-8 A study conducted over 5 years showed a low retreatment rate of about 2-3% per year, or a total of 13.6% over the course of the study, demonstrating UroLift™ System durability.9 Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.10 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift™ System) is recommended for the treatment of BPH in both the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines. 500,000 men have been treated with the UroLift™ System in select markets worldwide.11 Learn more at Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. About Barrigel™ Rectal SpacerBarrigel™ rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer.12 Barrigel™ rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA).13 Hyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide.14-15 Barrigel™ rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy12 and is cleared for rectal spacing in the United States, Australia, and Europe.16 Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease. For more information about Barrigel™ rectal spacer, please visit Barrigel™ Rectal Spacer Important Safety InformationBarrigel™ rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, it is the intent of Barrigel™ rectal spacer to reduce the radiation dose delivered to the anterior rectum. Barrigel™ rectal spacer is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient's body over time. Barrigel™ rectal spacer should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area. As with any medical treatment, there are some risks involved with the use of Barrigel™ rectal spacer. Potential complications associated with the use of Barrigel™ rectal spacer include, but are not limited to: pain associated with Barrigel™ rectal spacer injection; needle penetration of the bladder, prostate, rectal wall, rectum, or urethra; injection of Barrigel™ rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. More information on indications, contraindications, warnings and instructions for use can be found in the Instructions For Use at Individual results may vary. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are the property of their respective owners. © 2025 Teleflex Incorporated. All rights reserved. References*Paid consultants of Teleflex.**No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study †Studies sponsored by Teleflex. Chughtai et al, AUA 2025. Results from the CLEAR Randomized Controlled Trial (RCT) Suggest Factors Corresponding to Early Patient Satisfaction Are Better Following UroLift PUL Versus Rezum WVTT. † Roehrborn et al, AUA 2025. Patients Dissatisfied with BPH Medication in the IMPACT RCT Demonstrate Worse Patient Experience and Sleep Quality Before Crossing Over to UroLift PUL.† Roehrborn. Using the American Urological Association Quality Registry (AQUA) BPH Dataset to Assess Early Symptom Improvement after Treatment. Poster presented at AUA; April 26, 2025. Las Vegas, NV. Chao et al, AUA 2025. Safety of Stabilized Hyaluronic Acid (sHA) as a Rectal Spacer: Low Risk of Rectal Wall Infiltration and Reversibility. Shore, Can J Urol 2014 Rukstalis, Prostate Cancer and Prostatic Dis 2018 AUA BPH Guidelines 2003, 2020 McVary, Urology 2019 Roehrborn, Can J Urol 2017 Roehrborn, J Urol 2013 Management estimate based on product sales as of June 2024. Data on file Teleflex Interventional Urology. Mariados NF, Orio PF III, King MT et al. JAMA Oncol (2023). Barrigel Injectable Gel Instructions for Use (2022). Svatos M, Chell E, Low DA, et al. Symmetry, separation, and stability: Physical properties for effective dosimetric space with a stabilized hyaluronic acid spacer. Med Phys. 2024; 1-15. Restylane® celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers. 2021. Available at: Accessed Sept 30, 2021. Data on file Teleflex. 2025. Contacts:TeleflexLawrence KeuschVice President, Investor Relations and Strategy Media Contact:Glenn SilverPartner National Media Relations MAC03077-01 Rev A
Yahoo
10-04-2025
- Business
- Yahoo
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the 'Company'), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Aria Resort in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Guests are encouraged to register in advance by clicking HERE. Registration is recommended to secure your spot. Members of PROCEPT BioRobotics' management team presenting include: Reza Zadno – Chief Executive Officer Kevin Waters – Chief Financial Officer Sham Shiblaq – Chief Commercial Officer Barry Templin – Chief Technology Officer Clinical perspectives will also be provided by the following physicians: Dr. Inderbir Gill - Founding Executive Director for USC Urology, Chairman of Urological Cancer Surgery at Keck School of Medicine of USC Dr. Brian Helfand - Division Chief of Urology, Endeavor Health, Associate Chief Scientific Officer at Endeavor Health, Clinical Professor at University of Chicago, Ronald Chez Family and Richard Melman Family Endowed Chairman Dr. Gerald Park - Partner, Kansas City Urology Care A live webcast of the event, as well as an archived recording, will be available on the 'Investors' section of the Company's website at The webcast will be archived and available for replay for at least 90 days after the event. About PROCEPT BioRobotics CorporationPROCEPT BioRobotics' mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. Important Safety InformationAll surgical treatments have inherent and associated side effects. For a list of potential side effects visit Investor Contact:Matt BacsoVP, Investor Relations and Business in to access your portfolio
